language Türkçe
Article 2024 · 0 citations

Ascorbic acid mitigates doxorubicin-induced spleen injury in rats: Histopathological and immunohistochemical insights

Gezer, Arzu, Ozkaraca, Mustafa, Sari, Ebru Karadag, Bedir, Guersel, Aydin, Pelin, Asker, Hasan, Abd El-Aty, Am

Abstract

This study assessed the protective potential of ascorbic acid against doxorubicin-induced spleen tissue damage in rats. Twenty-eight male Sprague-Dawley rats were divided into four groups. The control group received saline every other day at a dose of 1mL throughout the experiment. The ascorbic acid group was administered 50mg/kg of ascorbic acid daily for 10 days. The doxorubicin group received a single dose of 15mg/kg of doxorubicin on day 7. The ascorbic acid + doxorubicin group received both 50mg/kg of ascorbic acid daily for 10 days and a single dose of 15mg/kg of doxorubicin on day 7. After the experiment, splenic tissue samples were examined histopathologically and immunohistochemically. Histopathological analysis revealed edema, destruction, and degeneration in the doxorubicin group, but these changes were alleviated in the ascorbic acid -treated group, approaching control group levels. Immunohistochemical analysis showed increased CD4(+) and CD8(+) cell immunopositivity in the ascorbic acid + doxorubicin group compared to the doxorubicin group. Biochemical tests indicated that doxorubicin reduced superoxide dismutase activity and increased malondialdehyde levels, whereas ascorbic acid mitigated these effects. The findings suggest that ascorbic acid may have a protective role against doxorubicin-induced spleen injury in rats.

Keywords
Ascorbic acid CD4(+) CD8(+) spleen doxorubicin splenotoxicity
WoS Categories
Pharmacology & Pharmacy
Sustainable Development Goals
Citation
Journal
PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
Year
2024
Volume
37
Issue
3
Pages
609-617
ISSN
1011-601X
DOI
10.36721/PJPS.2024.37.3.REG.609-617.1
WoS UID
WOS:001245024400010
Open via DOI